Evotec SE Company Top Insiders

EVOTF Stock  USD 8.01  0.00  0.00%   
Evotec SE employs about 4.7 K people. The company is managed by 10 executives with a total tenure of roughly 33 years, averaging almost 3.0 years of service per executive, having 471.5 employees per reported executive. Examination of Evotec SE's management performance can provide insight into the company performance.
Gabriele Hansen  President
Vice President Corporate Communications & Investor Relations
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Evotec SE Management Team Effectiveness

Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.
Evotec SE holds a total of 176.95 Million outstanding shares. Over half of Evotec SE's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Evotec SE in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Evotec SE, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Evotec SE Workforce Comparison

Evotec SE is rated # 4 in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 48,089. Evotec SE holds roughly 4,715 in number of employees claiming about 10% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.01) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.01.

Evotec SE Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Evotec SE Price Series Summation is a cross summation of Evotec SE price series and its benchmark/peer.

Evotec SE Notable Stakeholders

An Evotec SE stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evotec SE often face trade-offs trying to please all of them. Evotec SE's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evotec SE's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gabriele HansenVice President Corporate Communications & Investor RelationsProfile
Enno SpillnerCFO, Member of the Management BoardProfile
Craig JohnstoneCOO, Member of the Management BoardProfile
Matthias EversChief BoardProfile
Volker BraunVP ESGProfile
Cord DohrmannChief Scientific Officer and Member of Management BoardProfile
Monika ConradtGlobal HRProfile
Christian DargelEVP ComplianceProfile
MBA MBAChairman CEOProfile
Anja BoslerPrincipal AccountingProfile
String symbol = request.getParameter("s");

About Evotec SE Management Performance

The success or failure of an entity such as Evotec SE often depends on how effective the management is. Evotec SE management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evotec management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evotec management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people.

Evotec SE Workforce Analysis

Traditionally, organizations such as Evotec SE use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evotec SE within its industry.

Evotec SE Manpower Efficiency

Return on Evotec SE Manpower

Revenue Per Employee131.1K
Revenue Per Executive61.8M
Net Income Per Employee45.7K
Net Income Per Executive21.6M
Working Capital Per Employee9K
Working Capital Per Executive4.3M

Complementary Tools for Evotec Pink Sheet analysis

When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stocks Directory
Find actively traded stocks across global markets
CEOs Directory
Screen CEOs from public companies around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios